Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A updated results
Autor: | Peter C.C. Fong, Christian Heinrich Poehlein, Charles Schloss, Margitta Retz, Stéphane Oudard, Howard Gurney, Susan Feyerabend, William R. Berry, G. Gravis, Nataliya Mar, B. Laguerre, Evan Y. Yu, Ali Tafreshi, Josep M. Piulats, J. De Bono, Audrey E. Kam, J. A. Arranz, Heshui Wu, Marinela Augustin, Michael Paul Kolinsky |
---|---|
Rok vydání: | 2020 |
Předmět: |
Oncology
medicine.medical_specialty business.industry Urology Pembrolizumab Castration resistant lcsh:Diseases of the genitourinary system. Urology lcsh:RC870-923 lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease lcsh:RC254-282 Olaparib chemistry.chemical_compound Prostate cancer Docetaxel chemistry Internal medicine Cohort medicine business medicine.drug |
Zdroj: | European Urology Open Science, Vol 19, Iss, Pp e873-e874 (2020) |
ISSN: | 2666-1683 |
Databáze: | OpenAIRE |
Externí odkaz: |